1-3 of 3
Christopher W. Murray
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK

Joanne M. Munck, Valerio Berdini, Luke Bevan, Jessica L. Brothwood, Juan Castro, Aurélie Courtin, Charlotte East, Roberta Ferraldeschi, Tom D. Heightman, Christopher J. Hindley, Justyna Kucia-Tran, John F. Lyons, Vanessa Martins, Sandra Muench, Christopher W. Murray, David Norton, Marc O'Reilly, Michael Reader, David C. Rees, Sharna J. Rich, Caroline J. Richardson, Alpesh D. Shah, Lukas Stanczuk, Neil T. Thompson, Nicola E. Wilsher, Alison J.-A. Woolford, Nicola G. Wallis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (10): 1757–1768.
https://doi.org/10.1158/1535-7163.MCT-20-0909
Published: 01 October 2021
View article titled, ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
Open the PDF for ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK in another window
Includes: Supplementary data
Journal Articles

Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor

Timothy P.S. Perera, Eleonora Jovcheva, Laurence Mevellec, Jorge Vialard, Desiree De Lange, Tinne Verhulst, Caroline Paulussen, Kelly Van De Ven, Peter King, Eddy Freyne, David C. Rees, Matthew Squires, Gordon Saxty, Martin Page, Christopher W. Murray, Ron Gilissen, George Ward, Neil T. Thompson, David R. Newell, Na Cheng, Liang Xie, Jennifer Yang, Suso J. Platero, Jayaprakash D. Karkera, Christopher Moy, Patrick Angibaud, Sylvie Laquerre, Matthew V. Lorenzi
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (6): 1010–1020.
https://doi.org/10.1158/1535-7163.MCT-16-0589
Published: 01 June 2017
View article titled, Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
Open the PDF for Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor in another window
Includes: Supplementary data
Journal Articles

Abstract A211: Fragment‐based drug discovery of the synthetic small molecule HSP90 inhibitor AT13387

Christopher W. Murray, Maria G. Carr, Gianni Chessari, Miles Congreve, Joseph E. Coyle, Philip J. Day, Lynsey Fazal, Martyn Frederickson, Brent Graham, Jonathan Lewis, Rachel McMenamin, Alistair O'Brien, Sahil Patel, Glyn Williams, Andrew J. Woodhead, Alison J. Woolford
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A211.
https://doi.org/10.1158/1535-7163.TARG-09-A211
Published: 10 December 2009
View article titled, Abstract A211: Fragment‐based drug discovery of the synthetic small molecule HSP90 inhibitor AT13387